News

The authors in this multicenter, single-arm, open-label study evaluated the safety and efficacy of ibrutinib in 145 patients with relapsed or refractory del17p chronic lymphocytic leukemia (CLL). Overall response rate at 27.6 months was 83%. Additionally, 2-year progression-free and overall survivals were 63% and 75%, respectively. Grade 3 or worse infection rate was 30%. The […]

Rearrangement of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable (BCLU), particularly in the setting of double hit lymphoma (DHL). However, little is known about outcomes of patients who demonstrate MYC rearrangement without evidence of BCL2 or BCL6 rearrangement (single hit) or

The diagnosis of splenic marginal zone lymphoma (SMZL) is frequently a challenge, due to its lack of specific histological features and immunophenotypic markers, and the existence of other poorly characterized splenic lymphomas defying classification. The 7q32 deletion is a characteristic feature of SMZL, and its detection may help the differential diagnosis of splenic B-cell lymphomas.

The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAFV600-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies. In this double-blind, randomised, placebo-controlled,

On the basis of biologic factors and an improved understanding of the molecular development of the neural crest cells that give rise to neuroblastoma, neuroblastic tumors have been categorized into the following three biological types: Type 1:Characterized by gains and losses of whole chromosomes. It expresses the TrkA neurotrophin receptor, is hyperdiploid, and tends to

Until recently, if you wanted to know how a tumour was evolving, you had to take a biopsy of the cancer tissue and analyse it in a lab. This was clearly an invasive method for the patient, requiring a puncture, incision or surgery, and you could not use it to track the disease’s progression. Now,

In a recent study, molecular biomarkers were identified from an international discovery set of 673 medulloblastoma cases from the Medulloblastoma Advanced Genomics International Consortium. Risk stratification models were designed based on combined clinical and cytogenetic biomarkers identified in multivariable Cox proportional hazards analyses. Candidate biomarkers were tested using fluorescence in situ hybridization (FISH) on a

Five-year overall survival (OS) for children with B cell precursor acute lymphoblastic leukemia (B-ALL) exceeds 90% with risk-adapted therapy. Age, initial WBC count, genetic aberrations, and minimal residual disease (MRD) are used for risk stratification. Intrachromosomal amplification of a region of chromosome 21 (iAMP21; three or more extra copies of RUNX1 on an abnormal chromosome

Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality, 17p deletion, in patients who have been treated with at least one prior therapy. The newly approved drug targets the B-cell lymphoma 2 protein, which promotes cancer growth and often is

PDGFB rearrangements, 22q13.1 The PDGFB gene, located at chromosome 22, encodes the human platelet-derived growth factor (PDGF) B chain precursor and is the cellular homologue of the v-sis oncogene. The reciprocal translocations involving the chromosomal region 17q21.33 harboring the COL1A1 (a.k.a. OI4) gene, and the chromosomal region 22q13.1, harboring the PDGFB (a.k.a PDGF2) gene, t(17;22)(q21.3;q13.1),